retatrutide drug trial FDA Approval Status 2026: Everything We Know So Far Retatrutide, an experimental weight-loss drug,
Description
Glucagon-like peptide 1 (GLP-1) based therapies have seen a meteoric rise in popularity (about 300%1 increased use between 2018-2023)
Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity
Retatrutide, an innovative agent, represents a potential advancement in therapy
Further research is required
Although glucagon-like peptide-1 receptor agonist use may increase the risk for retained gastric contents in those undergoing endoscopic procedures, a 24-hour clear liquid diet may be “protective&rdquo
